

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 262 198 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
**04.12.2002 Bulletin 2002/49**

(51) Int Cl.7: **A61K 47/12, A61K 9/22,**  
**A61K 31/195, A61P 25/16**  
**// (A61K31/195, 31:195)**

(21) Application number: **02291229.9**

(22) Date of filing: **17.05.2002**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE TR**  
Designated Extension States:  
**AL LT LV MK RO SI**

(71) Applicant: **Pharma Pass S.A.**  
**67400 Illkirch (FR)**

(72) Inventor: **Seth, Pawan**  
**Irvine, CA 92612 (US)**

(30) Priority: **29.05.2001 US 866857**

(74) Representative: **Cabinet Hirsch**  
**34, Rue de Bassano**  
**75008 Paris (FR)**

**(54) Composition with sustained release of levodopa and carbidopa**

(57) The invention relates to a pharmaceutical composition comprising a therapeutically effective amount of levodopa and of carbidopa, dispersed in a hydrophilic matrix, said composition further comprising an organic acid.

A subject of the invention is also a process for preparing the composition, comprising granulation, in particular in a fluidized bed, of the various components and compression of the granules obtained.

**EP 1 262 198 A1**

**Description**Subject and summary of the invention

5 [0001] The present invention consists of a formulation with sustained release of a combination of two active principles, namely levodopa and carbidopa.

Prior art

10 [0002] In the case of two combined active principles, it is desirable, for certain dosage forms, for them to have:

- an extended release of the two active principles over a period of several hours, and with identical release profiles for the two substances;
- 15 - a stability of the formulation over time, for example over a period of at least 6 months under accelerated conditions as described in the European and American pharmacopoeias.

[0003] This is particularly true for levodopa and carbidopa combinations. Specifically, carbidopa is a relatively fragile molecule and formulations containing this product often show relatively poor conservation, particularly at high temperature and high humidity.

20 [0004] Various formulations corresponding to a levodopa/carbidopa combination with sustained release are disclosed in the literature.

[0005] Document US-A-5 840 756 discloses a matrix based on hydroxypropylmethylcellulose, hydroxypropylcellulose and a carboxyvinyl polymer and containing different proportions of levodopa and carbidopa. This formulation is obtained by direct compression of the mixture of the constituents. The drawback of such a process lies in the difficulty in obtaining a uniform distribution of the active principles during direct compression. This formulation does not have good stability.

[0006] Document EP-A-0 253 490 discloses a formulation of levodopa and carbidopa uniformly dispersed in a polymeric matrix consisting of a mixture of two polymers, one of which is water-soluble, such as hydroxypropyl(methyl) cellulose, and the other of which is weakly soluble, such as polyvinyl acetate/crotonic acid copolymer. Such a formulation is, firstly, complex (it requires the steps of mixing the active compounds with an aqueous-alcoholic solution of the polymers, drying, grinding, mixing with the lubricant and finally compressing into tablets), and secondly there is no indication as to the stability of the preparation.

30 [0007] No formulation of the prior art makes it possible simultaneously to obtain a parallel sustained release of the two principles with high stability over time, while at the same time being simple in its composition and implementation.

Summary of the invention

40 [0008] The invention relates to a pharmaceutical composition comprising a therapeutically effective amount of levodopa and of carbidopa, dispersed in a hydrophilic matrix, said composition further comprising an organic acid.

[0009] According to one embodiment, the organic acid is chosen from fumaric acid, citric acid, ascorbic acid, maleic acid, glutamic acid, malonic acid and oxalic acid.

[0010] According to one embodiment, the organic acid represents from 0.2% to 5% by weight relative to the weight of the composition.

45 [0011] According to one embodiment, the hydrophilic matrix represents from 10% to 80% by weight relative to the weight of the composition.

[0012] According to one embodiment, the hydrophilic matrix comprises hydroxypropylmethylcellulose.

[0013] According to one embodiment, the hydrophilic matrix comprises, as a percentage by weight relative to the weight of the composition, between 5% and 40% of hydroxypropylmethylcellulose with a viscosity of about 50 cP and between 5% and 40% by weight of hydroxypropylmethylcellulose with a viscosity of about 3 cP.

50 [0014] According to one embodiment, the hydrophilic matrix moreover comprises an insoluble substance.

[0015] According to one embodiment, the insoluble substance is microcrystalline cellulose.

[0016] According to one embodiment, the levodopa is present in an amount of between 50 mg and 300 mg.

[0017] According to one embodiment, the carbidopa is present in an amount of between 10 mg and 80 mg.

55 [0018] According to one embodiment, the composition is in the form of granules compressed together.

[0019] The composition according to the invention is useful in the treatment of Parkinson's disease.

[0020] The invention also relates to a process for preparing a composition according to the invention, comprising granulation of the various components and compression of the granules obtained.

[0021] According to one embodiment, the granulation is carried out in a fluidized bed.

#### Brief description of the figures

[0022]

Figure 1 represents the dissolution as a function of time of the composition of Example 1.

#### Description of the invention

[0023] The composition according to the invention comprises, in addition to the active principles, a hydrophilic matrix and an organic acid.

[0024] The Applicant has discovered, surprisingly, that the chemical stability of carbidopa can be greatly improved by incorporating into the formulation a small amount of an organic acid. This organic acid is typically a weak organic acid such as fumaric acid. Many other weak organic acids may be used to prevent the degradation of carbidopa, such as, for example, citric acid, maleic acid, tartaric acid, ascorbic acid or glutamic acid.

[0025] The hydrophilic matrix generally comprises a gelling substance such as hydroxypropylmethylcellulose. Other gelling components may be used, such as polyvinylpyrrolidone, poly(vinyl alcohol), hydroxypropylcellulose, hydroxymethylcellulose or gelatin, alone or as a mixture.

[0026] Mixtures of two different grades of hydroxypropylmethylcellulose, in particular of different viscosities (the viscosity is measured at 2% and at 20°C), are suitable.

[0027] The hydrophilic matrix may also comprise a substance, in general an insoluble substance such as microcrystalline cellulose. Other insoluble compounds may be used.

[0028] The amount of this insoluble substance present is generally in an insoluble substance:gelling substance weight ratio of between 15:100 and 50:100 and preferably 1:3.

[0029] Other conventional excipients may be used.

[0030] The invention is generally in the form of a tablet. This tablet is obtained in particular by compressing granules. These granules are advantageously obtained by granulating the constituent principles, for example according to a process in a fluidized air bed, followed by compression.

[0031] This process of granulation in a fluidized bed is conventional and known to those skilled in the art. According to the conventional art, a powder or a mixture of powders (active principles + excipients) is placed in suspension in the form of a fluidized bed in a granulator, and a solution containing a binder and, optionally, a surfactant is sprayed onto this bed to form granules. This technique of granulation in a fluidized bed is disclosed in particular in, for example, "Die Tablette", by Ritschel, Ed. Cantor Aulendorf, pages 211-212.

[0032] The granulate obtained is then mixed with a lubricant present in a proportion generally of between 0.1% and 5% by weight, such as, for example, magnesium stearate, sodium stearyl fumarate, glyceryl behenate or any other lubricant known to those skilled in the art and disclosed, for example, in Banker GS, Rhodes CT: Modern Pharmaceutics (1996) ISBN 0-8247-9371-4. In order to improve the flow of the mixture on the press, a flow regulator may also be added to the formulation, in a proportion generally of between 0.1% and 4% by weight. Such a substance may be, for example, talc, modified or unmodified starch, or, preferably, colloidal silica such as Aerosil® 200 manufactured by Degussa.

[0033] The conventional techniques of direct compression used in the prior art may also be used, although these are less preferred.

[0034] The tablets thus obtained are useful for treating Parkinson's disease. They also offer the advantage of avoiding the phenomena of "wearing-off and on-off" conventionally associated with standard formulations of levodopa and carbidopa, such as Sinemet® std.

[0035] The term "about" as used in the application means  $\pm 10\%$  of the value.

[0036] The examples which follow illustrate the invention without limiting it.

#### Examples

##### Example 1.

[0037] Granules are prepared from the following composition:

Levodopa	200.0 mg
Carbidopa (hydrate)	53.5 mg

(continued)

Hydroxypropylmethylcellulose 50 cP	60.0 mg
Hydroxypropylmethylcellulose 3 cP	90.0 mg
Microcrystalline cellulose	50.0 mg
Polyvinylpyrrolidone K30	15.0 mg
Fumaric acid	2.0 mg

**[0038]** The levodopa, the carbidopa, the microcrystalline cellulose and the two grades of hydroxypropylmethylcellulose are mixed together and placed in a fluidized air bed (GPCG1, Glatt®). A solution of polyvinylpyrrolidone in water is prepared and the fumaric acid is suspended in this solution. To do this, it is convenient to use a fumaric acid of micronized grade. The resulting suspension is sprayed onto the powder mixture at a pumping rate of 15 g/min, an inlet air temperature of about 55°C and a fluidized-air flow rate of 70 m³/h. A granulate is thus obtained.

**[0039]** The granulate obtained is mixed with 1% by weight of sodium stearyl fumarate and 0.5% by weight of colloidal silica (Aerosil 200). The mixture is compressed on a Fette P2100 rotary press equipped with punches with a diameter of 11 mm and a radius of curvature of 11 mm, to a mass of 415 mg and a hardness of 90 N. A rigorously identical formulation, but without fumaric acid, is then prepared and compressed to a mass of 413 mg.

Study of the degradation of carbidopa

Action of temperature on the formulation

**[0040]** A tablet of each of the formulations is placed in a graduated flask containing 50 ml of purified water and the mixture is stirred until the active principles have completely dissolved, and placed in an oven at 50°C for 72 hours. The carbidopa concentration in each of the two solutions is determined by high performance liquid chromatography according to the following method:

*Operating conditions:*

**[0041]**

*Mobile phase:* 5% ethanol  
95% monobasic sodium phosphate monohydrate (5.2 g/l)  
pH adjusted to 2.7 with orthophosphoric acid  
*Column:* NUCLEOSIL C18 5µ 250 x 4.6 mm  
*Detection:* 280 nm  
*Flow rate:* 1.2 ml/min  
*Volume injected:* 20 µl  
*Retention time:* Levodopa: 3.2 min  
Fumaric acid: 3.9 min  
Carbidopa: 5.5 min  
*Diluent:* 20% 1M H<sub>3</sub>PO<sub>4</sub> and 80% mobile phase

*Preparation of the standard solution:*

**[0042]** Introduce accurately weighed amounts of about 200 mg of reference levodopa and 53.5 mg of reference carbidopa into a 100 ml graduated flask. Dissolve with 20 ml of H<sub>3</sub>PO<sub>4</sub> in an ultrasonic bath for 5 minutes. Cool the solution to room temperature and make up to the graduation mark with the mobile phase. Take 10 ml of the solution and make up to 25 ml with the mobile phase. Filter a few ml of the suspension through a filter (0.45 µm).

**[0043]** The concentrations thus obtained are about:

Levodopa: 0.8 mg/ml  
Carbidopa: 0.214 mg/ml

*Preparation of the sample solution:*

**[0044]** Introduce an accurately weighed amount of powder obtained from ground tablets corresponding theoretically

to about 200 mg of levodopa and to about 53.5 mg of carbidopa into a 100 ml graduated flask. Dissolve with 20 ml of  $\text{H}_3\text{PO}_4$  in an ultrasonic bath for 10 minutes. Cool the solution to room temperature and make up to the graduation mark with the mobile phase (if necessary, wet the neck of the flask with ethanol to eliminate the foam). Take 10 ml of the solution and make up to 25 ml with the mobile phase. Filter a few ml of the suspension through a filter (0.45  $\mu\text{m}$ ).

*Calculating the results:*

[0045]

- The amount  $Q_1$ , expressed as % of levodopa, is given by the following formula:

$$Q_1 = (\text{Asam}/\text{Aref}) \times (\text{Wref}/\text{Wsam}) \times (\text{Vd sam}/\text{Vd ref}) \times (\text{Wth}/\text{C}) \times 100$$

where

Asam= Area of the peak for the sample solution

Aref= Area of the peak for the reference solution

Wref= Weight of the reference levodopa

Wsam= Weight of the sample

Vd sam= Dilution factor for the sample

Vd ref= Dilution factor for the reference

Wth= Theoretical weight of the tablet

C= Levodopa content of the tablet

- The amount  $Q_c$ , expressed as % of carbidopa, is given by the following formula:

$$Q_c = (\text{Asam}/\text{Aref}) \times (\text{Wref}/\text{Wsam}) \times (\text{Vd sam}/\text{Vd ref}) \times (\text{Wth}/\text{C}) \times 100$$

where

Asam= Area of the peak for the sample solution

Aref= Area of the peak for the reference solution

Wref= Weight of the reference carbidopa

Wsam= Weight of the sample

Vd sam= Dilution factor for the sample

Vd ref= Dilution factor for the reference

Wth= Theoretical weight of the tablet

C= Carbidopa content of the tablet

Results

[0046]

	Formulation with fumaric acid	Control formulation
Carbidopa (% of the initial value)	69.2	29.5

- [0047] A very marked protective effect of fumaric acid on the degradation of carbidopa is noted.

Action of light on the formulation

[0048] A tablet of each of the formulations is placed in a graduated flask containing 50 ml of purified water and the mixture is stirred until the active principles have completely dissolved, and exposed to the ambient laboratory light for 72 hours. The carbidopa concentration in each of the two solutions is determined by high performance liquid chromatography according to the following method:

## Results

[0049]

5

	Formulation with fumaric acid	Control formulation
Carbidopa (% of the initial value)	96.7	66.8

[0050] The light-stability of carbidopa is also considerably improved by the invention.

10 [0051] The release of active principle by the above formulation is studied according to the method described in the edition of the US pharmacopoeia in force and with the following parameters:

Dissolution medium: 0.1M pH 2.0 citrate buffer

Volume: 1000 ml

15

Wavelength: 280 nm

Dissolution tool: 40 mesh basket

Stirring speed: 100 rpm

HPLC assay to separate the active principles

20 [0052] The dissolution curve is given in Figure 1.

[0053] The dissolution profile obtained shows a sustained release of the active principle over about 5 hours.

Example 2.

25 [0054] The above example is repeated, but replacing the fumaric acid with ascorbic acid (these acids are used in the same amounts) . The formulation used is as follows:

30

Levodopa	200.0 mg
Carbidopa (hydrate)	53.5 mg
Hydroxypropylmethylcellulose 50 cP	80.0 mg
Hydroxypropylmethylcellulose 3 cP	70.0 mg
Microcrystalline cellulose	50.0 mg
Polyvinylpyrrolidone K30	15.0 mg
Ascorbic acid	2.0 mg

35

[0055] The stability of the carbidopa in the above two formulations is studied according to the protocol described previously, with exposure to heat or to light.

## 40 Results

Action of heat (50°C for 72 hours)

[0056]

45

	Formulation with ascorbic acid	Control formulation
Carbidopa (% of the initial value)	58.6	29.5

50

Action of light (ambient laboratory light for 72 hours)

[0057]

55

	Formulation with ascorbic acid	Control formulation
Carbidopa (% of the initial value)	94.3	66.8

[0058] The stability is still improved with ascorbic acid (although in a slightly lower proportion relative to the formulation

containing fumaric acid).

[0059] The release of the active principles shows a profile similar to that of the preceding formulation (although slightly slower, possibly on account of the presence of a larger amount of microcrystalline cellulose).

#### 5 Example 3.

[0060] A tablet having the following composition is prepared:

Levodopa	200.00 mg
Carbidopa (hydrate)	53.50 mg
Hydroxypropylmethylcellulose 50 cP	50.00 mg
Hydroxypropylmethylcellulose 3 cP	50.00 mg
Colloidal silicon dioxide	2.40 mg
Fumaric acid	10.00 mg
FD&C yellow 10	0.03 mg
FD&C red 3	0.03 mg
Sodium stearyl fumarate	7.30 mg

[0061] A 300mg water solution is prepared by dissolving the hydroxypropylmethylcellulose 3cP grade. The dyes are dissolved in 100mg of water and the micronised fumaric acid is suspended in the solution. These two solutions are then mixed together. The levodopa, the carbidopa, the colloidal silicon dioxide and the hydroxypropylmethylcellulose 50cP grade are mixed together and placed in a fluidized air bed (GPCG1, Glatt®). The previously prepared solution is sprayed onto the powder mixture at a pumping rate of 15 g/min, an inlet air temperature of about 55°C and a fluidized-air flow rate of 70 m<sup>3</sup>/h. A granulate is thus obtained.

[0062] The granulate obtained is mixed with the sodium stearyl fumarate. The mixture is compressed on a Fette P2100 rotary press as previously disclosed.

#### 30 Example 4.

[0063] Example 3 is repeated, but with the following composition:

Levodopa	200.00 mg
Carbidopa (hydrate)	53.50 mg
Hydroxypropylmethylcellulose 50 cP	35.00 mg
Hydroxypropylmethylcellulose 3 cP	50.00 mg
Colloidal silicon dioxide	2.40 mg
Fumaric acid	10.00 mg
FD&C yellow 10	0.03 mg
FD&C red 3	0.03 mg
Sodium stearyl fumarate	7.00 mg

[0064] Both example 3 and example 4 compositions exhibit improved stability and sustained release.


#### Claims

1. Pharmaceutical composition comprising a therapeutically effective amount of levodopa and of carbidopa, dispersed in a hydrophilic matrix comprising a gelling substance, said hydrophilic matrix representing from 10% to 80% by weight relative to the weight of the composition, said composition further comprising an organic acid.
2. Composition according to claim 1, in which the organic acid is chosen from fumaric acid, citric acid, ascorbic acid, maleic acid, glutamic acid, malonic acid and oxalic acid.
3. Composition according to claim 1 or 2, in which the organic acid represents from 0.2% to 5% by weight relative to the weight of the composition.

4. Composition according to any one of claims 1 to 3, in which the hydrophilic matrix comprises hydroxypropylmethylcellulose, polyvinylpyrrolidone, poly(vinyl alcohol), hydroxypropylcellulose, hydroxymethylcellulose or gelatin, alone or as a mixture.
5. Composition according to any one of claims 1 to 4, in which the hydrophilic matrix comprises hydroxypropylmethylcellulose.
6. Composition according to any one of claims 1 to 5, in which the hydrophilic matrix comprises, as a percentage by weight relative to the weight of the composition, between 5% and 40% of hydroxypropylmethylcellulose with a viscosity of about 50 cP and between 5% and 40% by weight of hydroxypropylmethylcellulose with a viscosity of about 3 cP.
7. Composition according to any one of claims 1 to 6, in which the hydrophilic matrix moreover comprises an insoluble substance.
8. Composition according to Claim 7, in which the insoluble substance is microcrystalline cellulose.
9. Composition according to any one of claims 1 to 8, in which the levodopa is present in an amount of between 50 mg and 300 mg.
10. Composition according to any one of claims 1 to 8, in which the carbidopa is present in an amount of between 10 mg and 80 mg.
11. Composition according to any one of claims 1 to 10, in the form of granules compressed together.
12. Composition according to any one of claims 1 to 10, for its use for the treatment of Parkinson's disease.
13. Process for preparing a pharmaceutical composition according to any one of claims 1 to 10, comprising:
  - (a) mixing a therapeutically effective amount of levodopa and of carbidopa with a hydrophilic matrix;
  - (b) granulation of the various components of step (a); and
  - (c) compression of the granules obtained from step (b).
14. Process according to Claim 13, in which the granulation is carried out in a fluidized bed.



Figure 1





European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 02 29 1229

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	US 5 532 274 A (WENZEL UDO PROF DR ET AL) 2 July 1996 (1996-07-02) * column 3-4; examples 14,15 *	1-4,7, 9-14	A61K47/12 A61K9/22 A61K31/195 A61P25/16 /(A61K31/195, 31:195)
X	WO 99 04765 A (BRAMBILLA GAETANO ;MEZZADRI ROSA (IT); VENTURA PAOLO (IT); ACERBI) 4 February 1999 (1999-02-04) * example 14 *	1-3,7, 9-14	
D,X	EP 0 253 490 A (MERCK & CO INC) 20 January 1988 (1988-01-20)	13,14	
A	* page 4, line 29-32 *	1-12	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K A61P
The present search report has been drawn up for all claims			
Place of search <b>MUNICH</b>		Date of completion of the search <b>6 September 2002</b>	Examiner <b>Herrera, S</b>
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.82 (P04001)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 29 1229

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

06-09-2002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5532274	A	02-07-1996	DE 4101873 A1	30-07-1992
			AT 147264 T	15-01-1997
			AU 658171 B2	06-04-1995
			AU 1186892 A	27-08-1992
			BG 61677 B1	31-03-1998
			BG 97894 A	25-04-1994
			CA 2101164 A1	24-07-1992
			CZ 280847 B6	17-04-1996
			CZ 9203692 A3	15-09-1993
			WO 9212710 A1	06-08-1992
			DE 59207852 D1	20-02-1997
			DK 568577 T3	30-06-1997
			EE 3016 B1	15-08-1997
			EP 0568577 A1	10-11-1993
			ES 2098496 T3	01-05-1997
			FI 933304 A	22-07-1993
			GR 3022993 T3	30-07-1997
			JP 6504543 T	26-05-1994
			LT 555 A , B	25-11-1994
			LV 11103 A	20-04-1996
			LV 11103 B	20-06-1996
			RO 114737 B1	30-07-1999
			RU 2114619 C1	10-07-1998
			SK 369292 A3	04-02-1998
			US 5624960 A	29-04-1997
WO 9904765	A	04-02-1999	IT MI971746 A1	25-01-1999
			AU 743186 B2	17-01-2002
			AU 8977798 A	16-02-1999
			BG 103253 A	30-09-1999
			BR 9801335 A	04-05-1999
			CN 1267215 T	20-09-2000
			WO 9904765 A2	04-02-1999
			EP 1003486 A2	31-05-2000
			HU 0003897 A2	28-08-2001
			JP 2001510789 T	07-08-2001
			NO 991376 A	25-05-1999
			NZ 502479 A	01-02-2002
			PL 338502 A1	06-11-2000
			SK 922000 A3	11-07-2000
			TR 9900675 T1	22-11-1999
			US 6284272 B1	04-09-2001
			US 2002051752 A1	02-05-2002
EP 0253490	A	20-01-1988	AT 58473 T	15-12-1990
			AU 597670 B2	07-06-1990

EPO FORM P0159

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 29 1229

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

06-09-2002

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0253490      A	AU	7422887 A	17-12-1987
	CY	1578 A	20-12-1991
	DE	3766308 D1	03-01-1991
	DK	170514 B1	09-10-1995
	EP	0253490 A1	20-01-1988
	GR	3001102 T3	12-05-1992
	HK	56191 A	26-07-1991
	IE	60508 B	27-07-1994
	IL	82823 A	10-03-1991
	JP	1715235 C	27-11-1992
	JP	4000045 B	06-01-1992
	JP	63054319 A	08-03-1988
	KR	9502882 B1	28-03-1995
	NZ	220599 A	26-10-1990
	PT	85049 A , B	01-07-1987
	SG	52191 G	23-08-1991
	US	4900755 A	13-02-1990
	US	4983400 A	08-01-1991
	ZA	8704233 A	14-12-1987
	ZA	8809189 A	30-08-1989
<hr/>			

EPO FORM P459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82